omniture
logo
Search
智康弘义BIOCITY
Media Room

Latest News

rss

BioCity presents late-breaking clinical trial results with SC0062 for IgA Nephropathy at ASN Kidney Week 2024 as published in the Journal of the American Society of Nephrology

SHANGHAI, Nov. 4, 2024 /PRNewswire/ -- BioCity Biopharma (BioCity) announced late-breaking results ...

2024-11-05 11:09 1413

BioCity will present the late-breaking clinical trial data of its ETA selective antagonist SC0062 at the American Society of Nephrology (ASN) 2024 with simultaneous publication of the trial data in the Journal of the American Society of Nephrology (JASN)

SHANGHAI, Oct. 14, 2024 /PRNewswire/ -- BioCity Biopharma announced that a late-breaking clinical t...

2024-10-14 15:38 1478

Breakthrough Therapy Designation (BTD) for BioCity's SC0062, a selective endothelin type A (ETA) antagonist, granted by National Medical Products Administration for IgA nephropathy (IgAN) with proteinuria

SHANGHAI, Sept. 26, 2024 /PRNewswire/ -- BioCity Biopharma (BioCity) announced its endothelin recep...

2024-09-26 15:10 1385

Impressive preliminary objective response rates (ORR) of 36% in NSCLC and 80% in EGFRmut NSCLC: Interim Results of a Phase 1 Study of BC3195, a First-in-Class ADC Targeting CDH3, Presented by BioCity at ESMO 2024

SHANGHAI, Sept. 23, 2024 /PRNewswire/ -- On September 14, 2024, BioCity presented interim clinical ...

2024-09-23 17:40 1763

BioCity announces its endothelin receptor A selective antagonist SC0062 met the primary endpoint in IgA nephropathy in 2-SUCCEED trial: a randomized, double-blind, placebo-controlled Phase 2 trial

SHANGHAI, July 8, 2024 /PRNewswire/ -- BioCity Biopharma (BioCity) announced its endothelin recepto...

2024-07-08 13:41 1589

BioCity Announces FDA Clearance of the Investigational New Drug Application for its First-In-Class Antibody Drug Conjugate Targeting Glypican 3

SHANGHAI, April 9, 2024 /PRNewswire/ -- BioCity Biopharma today announced that the U.S. Food and Dr...

2024-04-09 22:10 1627

BioCity Announces Enrollment Completion of the IgA Nephropathy (IgAN) Cohort in the Randomized, Placebo-controlled Phase II Clinical Trial of the ETA Receptor Antagonist SC0062

WUXI, China, Feb. 25, 2024 /PRNewswire/ -- BioCity Biopharma is pleased to announce the completion ...

2024-02-26 22:38 1318

BioCity announces the first patient dosed with its anti-TIM-3 mAb BC3402 in Combination with IMFINZI for the Treatment of Advanced Hepatocellular Carcinoma in a Phase Ib/II Trial

WUXI, China, Dec. 20, 2023 /PRNewswire/ -- BioCity Biopharma today announced dosing of the first p...

2023-12-21 08:26 1655

Riding the tide, realize the future: The BD paths for Chinese Biotech

WUXI, China, Nov. 14, 2023 /PRNewswire/ -- 2023 BIO-Europe just closed last week. In line with prev...

2023-11-15 10:42 1275

BioCity Signs Collaboration Agreement with AstraZeneca on BC3402, a monoclonal antibody targeting anti-TIM-3, in Combination with IMFINZI (durvalumab) for the Treatment of Advanced Hepatocellular Carcinoma in China

WUXI, China, Sept. 27, 2023 /PRNewswire/ -- September 25th, 2023, BioCity Biopharma and AstraZeneca...

2023-09-28 09:46 1995

BioCity announces FDA clearance of Investigational New Drug application for its first-in-class CD3/EGFR bispecific antibody

WUXI, China, Aug. 7, 2023 /PRNewswire/ -- BioCity Biopharma today announced that the U.S. Food and ...

2023-08-07 16:14 1369

BioCity announces the first patient dosed with its first-in-class CDH3-targeting ADC BC3195 in a Phase 1 Trial

WUXI, China, July 19, 2023 /PRNewswire/ -- BioCity Biopharma, a clinical-stage biopharmaceutical co...

2023-07-20 10:41 1969
BioCity announces the first patient dosed with its first-in-class CDH3-targeting ADC BC3195 in a Phase 1 Trial

BioCity Announces Initiation of a Phase 2 Trial for SC0062, a Promising ETA Receptor Antagonist for Chronic Kidney Disease

WUXI, China, June 21, 2023 /PRNewswire/ -- BioCity Biopharma, a clinical-stage biopharmaceutical co...

2023-06-22 08:02 2221